Overview

Metabolomics Market is poised to register a CAGR of 12.2% during the forecast period 2022 to 2028. 

FutureWise Market Research has instantiated a report that provides an intricate analysis of Metabolomics Market  trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Metabolomics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Metabolomics Market:
• Waters Corporation (US)
• Agilent Technologies (US)
• Shimadzu Corporation (Japan)
• Thermo Fisher Scientific (US)
• Danaher Corporation (US)
• Bruker Corporation (US)
• PerkinElmer (US)
• Merck KGaA (Germany)
• GE Healthcare (US)
• Hitachi High-Technologies Corporation (Japan)
• Human Metabolome Technologies, Inc. (Japan)
• LECO Corporation (US)
• Metabolon, Inc. (US)
• Bio-Rad Laboratories (US)
• Scion Instruments (US)
• DANI Instruments S.p.A. (Italy)
• GL Sciences (Japan)
• SRI Instruments (US)
• Kore Technology Ltd. (UK)
• JASCO, Inc. (US)
(Note: The list of the major players will be updated with the latest market scenario and trends)

Metabolomics Market Segmentation:
By Product & Service
• Metabolomics Instruments
 o Separartion Tools
    o Gas Chromatography
    o High-performance Liquid Chromatography
    o Ultra-performance Liquid Chromatography
    o Capillary Electrophoresis
 o Detection Tools
    o Nuclear Magnetic Resonance (NMR) Spectroscopy
    o Mass Spectrometry (MS)
    o Surface-Based Mass Analysis
• Metabolomics Bioinformatics Tools & Services
 o Bioinformatics Services
 o Bioinformatics Tools and Databases

By Application
• Biomarker discovery
• Drug discovery
• Toxicology testing
• Nutrigenomics
• Functional Genomics
• Personalized medicine
• Other Applications

By Indication
• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Metabolic Disorders
• Inborn Errors of Metabolism
• Other Indications

By End User
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Other End Users

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Metabolomics Market By Product & Service, By Application, By Indication, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Metabolomics Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Metabolomics Market Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Metabolomics Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Metabolomics Market, By Product & Service  Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Metabolomics Instruments
       7.1.1. Separartion Tools
              7.1.1.1. Gas Chromatography
              7.1.1.2. High-performance Liquid Chromatography
              7.1.1.3. Ultra-performance Liquid Chromatography
              7.1.1.4. Capillary Electrophoresis
       7.1.2. Detection Tools
              7.1.2.1. Nuclear Magnetic Resonance (NMR) Spectroscopy
              7.1.2.2. Mass Spectrometry (MS)
              7.1.2.3. Surface-Based Mass Analysis
  7.2. Metabolomics Bioinformatics Tools & Services
       7.2.1. Bioinformatics Services
       7.2.2. Bioinformatics Tools and Databases

8. Metabolomics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)
  8.1. Biomarker discovery
  8.2. Drug discovery
  8.3. Toxicology testing
  8.4. Nutrigenomics
  8.5. Functional Genomics
  8.6. Personalized medicine
  8.7. Other Applications

9. Metabolomics Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million)
  9.1. Cancer
  9.2. Cardiovascular Disorders
  9.3. Neurological Disorders
  9.4. Metabolic Disorders
  9.5. Inborn Errors of Metabolism
  9.6. Other Indications

10. Metabolomics Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)
   10.1. Academic and Research Institutes
   10.2. Pharmaceutical & Biotechnology Companies
   10.3. Contract Research Organizations
   10.4. Other End Users

11. North America Metabolomics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  11.1. Introduction
  11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       11.2.1. U.S.A
       11.2.2. Canada
       11.2.3. Mexico
  11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Metabolomics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Brazil
         12.2.2. Venezuela
         12.2.3. Argentina
         12.2.4. Rest of Latin America
   12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Metabolomics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Germany
         13.2.2. U.K        
         13.2.3. France
         13.2.4. Italy
         13.2.5. Spain
         13.2.6. Russia
         13.2.7. Poland
         13.2.8. Rest of Europe
   13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Metabolomics Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. Japan
         14.2.2. China
         14.2.3. India
         14.2.4. Australia and New Zealand
         14.2.5. ASEAN
         14.2.6. Rest of Asia Pacific
   14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         15.2.1. GCC
         15.2.2. Israel
         15.2.3. South Africa
         15.2.4. Rest of MEA
   15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape  
   16.1. Global Landscape - Key Players, Revenue and Presence
   16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   16.3. Global Emerging Companies
   16.4. North America - Market Share Analysis and Key Regional Players
   16.5. Europe - Market Share Analysis and Key Regional Players
   16.6. Asia Pacific - Market Share Analysis and Key Regional Players
   16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   17.1. Waters Corporation (US)
         17.1.1. Company Overview
         17.1.2. Product Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2. Agilent Technologies (US)
         17.2.1. Company Overview
         17.2.2. Product Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. Shimadzu Corporation (Japan)
         17.3.1. Company Overview
         17.3.2. Product Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. Thermo Fisher Scientific (US)
         17.4.1. Company Overview
         17.4.2. Product Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
   17.5. Danaher Corporation (US)
         17.5.1. Company Overview
         17.5.2. Product Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
   17.6. Bruker Corporation (US)
         17.6.1. Company Overview
         17.6.2. Product Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. PerkinElmer (US)
         17.7.1. Company Overview
         17.7.2. Product Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Merck KGaA (Germany)
         17.8.1. Company Overview
         17.8.2. Product Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. GE Healthcare (US)
         17.9.1. Company Overview
         17.9.2. Product Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
   17.10.Hitachi High-Technologies Corporation (Japan)
         17.10.1.Company Overview
         17.10.2.Product Portfolio
         17.10.3.SWOT Analysis
         17.10.4.Financial Overview
         17.10.5.Strategic Overview
   17.11.Human Metabolome Technologies, Inc. (Japan)
         17.11.1.Company Overview
         17.11.2.Product Portfolio
         17.11.3.SWOT Analysis
         17.11.4.Financial Overview
         17.11.5.Strategic Overview
   17.12.LECO Corporation (US)
         17.12.1.Company Overview
         17.12.2.Product Portfolio
         17.12.3.SWOT Analysis
         17.12.4.Financial Overview
         17.12.5.Strategic Overview
   17.13.Metabolon, Inc. (US)
         17.13.1.Company Overview
         17.13.2.Product Portfolio
         17.13.3.SWOT Analysis
         17.13.4.Financial Overview
         17.13.5.Strategic Overview
   17.14.Bio-Rad Laboratories (US)
         17.14.1.Company Overview
         17.14.2.Product Portfolio
         17.14.3.SWOT Analysis
         17.14.4.Financial Overview
         17.14.5.Strategic Overview
   17.15.Scion Instruments (US)
         17.15.1.Company Overview
         17.15.2.Product Portfolio
         17.15.3.SWOT Analysis
         17.15.4.Financial Overview
         17.15.5.Strategic Overview
   17.16.DANI Instruments S.p.A. (Italy)
         17.16.1.Company Overview
         17.16.2.Product Portfolio
         17.16.3.SWOT Analysis
         17.16.4.Financial Overview
         17.16.5.Strategic Overview
   17.17.GL Sciences (Japan)
         17.17.1.Company Overview
         17.17.2.Product Portfolio
         17.17.3.SWOT Analysis
         17.17.4.Financial Overview
         17.17.5.Strategic Overview
   17.18.SRI Instruments (US)
         17.18.1.Company Overview
         17.18.2.Product Portfolio
         17.18.3.SWOT Analysis
         17.18.4.Financial Overview
         17.18.5.Strategic Overview
   17.19.Kore Technology Ltd. (UK)
         17.19.1.Company Overview
         17.19.2.Product Portfolio
         17.19.3.SWOT Analysis
         17.19.4.Financial Overview
         17.19.5.Strategic Overview
   17.20.JASCO, Inc. (US)
         17.20.1.Company Overview
         17.20.2.Product Portfolio
         17.20.3.SWOT Analysis
         17.20.4.Financial Overview
         17.20.5.Strategic Overview

18. Pre and Post COVID-19 Impact
   18.1. Positive influence on the healthcare industry
   18.2. The financial disruption of the manufacturing sector
   18.3. Impact of COVID-19 on emerging companies
   18.4. Significant mandates in the healthcare regulations initiated by administrations
   18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures